Company Overview
QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems with low frequency sound waves for detection, diagnosis, and treatment of diseases in the United States and Internationally. The company offers QT Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. It serves patients, medical professionals, and radiologists. The company has a collaboration with Olea Medical S.A.S for the development of QTI Imaging-Olea Viewer; and a strategic partnership with Intelerad Medical Systems Incorporated. QT Imaging Holdings, Inc. was founded in 2012 and is headquartered in Novato, California.
Recent Developments
- Dec 2025 Revenue of $18.93M (+287.9% YoY); net profit $-21.08M.
- Trailing 12 Months Year-on-year growth — revenue +103.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 103.20% |
Stock Price Performance
| 1 Year: | -90.64% |
| 6 Months: | -53.82% |
| 3 Months: | -26.84% |
| 1 Month: | +1.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.54 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QTI QT Imaging Holdings, Inc. PHARMA | 2.78 | -2.00 | $40.69M | 0.00% | -29.28% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 7.56K | 3.18K | 24.66K | 1.36M | 1.71M | 955.97K | - | 2.80M | 3.66M | 4.19M | 8.28M | 6.53M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 986.00K | 1.83M | 2.39M | 5.13M | 3.86M |
| Gross Profit | - | - | - | - | - | -39.01K | 62 | 858 | 760.08K | 874.55K | 605.30K | - | 1.81M | 1.83M | 1.80M | 3.14M | 2.67M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 2.85M | 2.87M | 3.45M | 3.84M | 5.02M |
| Operating Income | -35.75K | -142.97K | -612.88K | -973.85K | -1.10M | -1.75M | -1.20M | -1.24M | -5.58M | -2.22M | -2.33M | - | -1.04M | -1.04M | -1.65M | -700.21K | -2.35M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -10.41M | -3.58M | -3.95M | -372.35K | -2.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 691.00K | 378.90K | 564.73K | 1.00M | 930.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -11.14M | -4.00M | -4.56M | -1.39M | -3.41M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.78K | 0 | -3.78K | - |
| Net Income | -35.75K | -204.23K | -369.94K | -636.07K | -395.77K | -1.88M | -1.33M | -1.38M | -628.59K | -1.25M | -3.62M | - | -11.14M | -4.00M | -4.56M | -1.39M | -3.41M |
| Diluted EPS | - | - | -0.06 | -0.13 | -0.16 | -0.20 | -0.14 | -0.14 | -0.05 | -0.30 | -0.51 | - | -1.21 | -0.14 | -0.47 | -0.10 | -0.25 |
| R&D Expense | - | - | - | - | - | 421.89K | 349.66K | 311.83K | 642.55K | 925.08K | 925.21K | - | 852.25K | 900.69K | 938.76K | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 40.35K | 4.88M | 18.93M |
| Cost of Revenue | - | 556.92K | 134.99K | 2.24M | 10.34M |
| Gross Profit | - | 0 | -94.63K | 2.64M | 8.58M |
| Operating Expenses | - | 4.28M | 4.91M | 14.82M | 13.02M |
| Operating Income | - | -4.28M | -5.01M | -12.18M | -4.44M |
| EBITDA | - | -2.26M | -5.07M | -4.27M | -18.31M |
| Interest Expense | - | 23.10K | 544.83K | 4.50M | 2.64M |
| Pretax Income | - | -2.29M | -6.10M | -9.00M | -21.08M |
| Tax Provision | - | 486.62K | 1.60K | -16.00K | -1.00K |
| Net Income | - | -2.77M | -6.10M | -8.98M | -21.08M |
| Diluted EPS | - | -0.87 | -1.92 | -0.71 | -2.01 |
| R&D Expense | - | - | 1.49M | 3.27M | 3.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 41.95M | 6.71M | 6.09M | 23.02M |
| Current Assets | - | 250.70K | 4.82M | 4.92M | 22.09M |
| Cash & Equivalents | - | 78.20K | 164.69K | 1.17M | 10.41M |
| Inventory | - | 4.78M | 4.42M | 3.14M | 5.03M |
| Receivables | - | 0 | 1.29K | 67.00K | 5.78M |
| Total Liabilities | - | 13.42M | 12.02M | 15.62M | 16.58M |
| Current Liabilities | - | 4.19M | 7.34M | 9.79M | 7.87M |
| Long Term Debt | - | 6.00M | 3.24M | 3.86M | 4.58M |
| Total Debt | - | 861.37K | 9.57M | 9.91M | 5.24M |
| Total Equity | - | 28.53M | -5.31M | -9.54M | 6.45M |
| Shares Outstanding | - | 21.32M | 21.32M | 26.77M | 11.90M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -1.26M | -2.65M | -10.03M | -8.96M |
| Investing Cash Flow | - | 192.24M | -13.04K | -88.00K | -124.00K |
| Financing Cash Flow | - | -191.32M | 2.37M | 11.13M | 18.35M |
| Capital Expenditure | - | -22.60K | -13.04K | -88.00K | -124.00K |
| Free Cash Flow | - | -1.26M | -2.66M | -10.12M | -9.08M |
| Net Change in Cash | - | -343.35K | -290.39K | 1.01M | 9.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | -234.5% | 54.1% | 45.4% |
| Operating Margin % | - | - | -12,409.8% | -249.6% | -23.4% |
| Net Margin % | - | - | -15,113.2% | -184.2% | -111.4% |
| ROE % | - | -9.7% | 114.8% | 94.2% | -327.1% |
| ROCE % | - | -11.3% | 792.4% | 328.5% | -29.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Lynrock Lake LP | 9.33% | 1.11M | $2.90M |
| 2 | Alyeska Investment Group, L.p. | 5.89% | 702.78K | $1.83M |
| 3 | Vanguard Capital Management LLC | 2.99% | 356.45K | $930.33K |
| 4 | Bleichroeder LP | 2.66% | 316.67K | $826.50K |
| 5 | Geode Capital Management, LLC | 1.14% | 135.42K | $353.44K |
| 6 | Citadel Advisors Llc | 0.96% | 114.10K | $297.80K |
| 7 | Perkins Capital Management, Inc. | 0.84% | 100.00K | $261.00K |
| 8 | Stonepine Capital Management, LLC | 0.84% | 100.00K | $261.00K |
| 9 | Blackrock Inc. | 0.51% | 61.35K | $160.13K |
| 10 | Millennium Management Llc | 0.46% | 55.34K | $144.44K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QTI
QT Imaging Approaches Breakeven In The Perfect Cultural Moment (NASDAQ:QTI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNejFMOTFTaHRnSG9xSGJORDlEa0VhX0g2YlhWY2dFYUwyV3g0OWlZX1dPVnRJTHBDZmxQS0RabDMzSnE2bF9UVlhQZVJBYUwzSmZlQ1gwb2s0MHMwam1nYzdqdHIzSWdUaHh5eDdQTkY3anNuRXFtbHJCa01iTFdnQVY2NjlfMGxNR0U3Wk…
QT Imaging (QTI) awards its CEO 484K RSUs that vest through 2030, with all shares accelerating if the company undergoes a change of control. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNb280Vkp4RmRySnVjNkM0WmwzMkRHeWwtQnJuT0pSUVN3TTNFZ04wcE1XNVBiQ2VzVnlfeTY2NTE4dnl2djBIaUlvU1BEbGdTQzlWbjJYSTdBdldpMmFLbFZsSjlpZGsxWUdnQk9HcE41bFNkdFRjMlBWNmxyN2JnWEVKTWlJRzdydnRLV2…
QT Imaging Holdings, Inc. Common Stock (NASDAQ: QTI) Share Price, QTI Stock News, QTI Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE1wUXNfUm9CVFJ1MTFpSnZPLUJETnphQ3ZyLUtVT1BOcTNHNFVucnJvV2VfZXNkYXhGeW03UHUyaG5fRFBIVHhNRHZ4QnNhT0l2TFV3Sw?oc=5" target="_blank">QT Imaging Holdings, Inc. Common Stock (NASDAQ: QTI) …
QT IMAGING ($QTI) Releases Q2 2026 Earnings | QTI Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxQbC1lenkxYXgtTmZRakVhZjRySFlGOVFLUVVCcEppdjR6LUY5c1NLZVgyRUp0TER5MDEyNVVmRG1sUzdvdF9ESEVYQnV4QUlWQ3VCcVc3V1M2b3Ntb0ROTjUyQWZYcWZzUzZudmxYZ1RocVVESXg2el9oeHhpUXZMd01NMkYxWENsd2c?oc…
QT Imaging Holdings Announces Results of 2026 Annual Stockholder Meeting - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNcWV3N0lPeUc2MFVEeHA5MkpDWHEtcEdCOE1ZWHF1X0FlVXV2U3FUVVZ1dVd2bFFxU3N4MmpFdUk1Z3Rwc2xDMTlSMjk3Njc5TjRnZzdiVVZqdktvMlhHY1NwUkxTMW9ta3hvb1JHX0dFbzNWWTlqekVNQjJVSGxBY3l1V3FkOEk0M1BpN0…
QT Imaging Holdings, Inc. Common Stock (NASDAQ: QTI) Share Price, QTI Stock News, QTI Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE9YLUFYVTI4QU1ET2xVUTd4a3p3cUo4UkllZlhDRllQUnl1NGZ1Ui1NNklaZktkYWR3WWVSTXhnU2tjVFlwSlRaLUxLSFFtZXc?oc=5" target="_blank">QT Imaging Holdings, Inc. Common Stock (NASDAQ: QTI) Share P…
QTI — Frequently Asked Questions
What is the current share price of QT Imaging Holdings, Inc. (QTI)?
As of 2026-09-19 21:16 PDT, QT Imaging Holdings, Inc. (QTI) trades at $2.78 on NasdaqCM. Its 52-week range is $2.63 to $39.75.
What is the market capitalisation of QTI?
QT Imaging Holdings, Inc. (QTI) has a market capitalisation of $40.69M on NasdaqCM.
What is the P/E ratio of QTI?
QTI trades at a trailing price-to-earnings (P/E) ratio of -2.00. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.01.
Is QTI a good stock to buy?
This page provides a data-driven analysis of QT Imaging Holdings, Inc. (QTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.